Trump’s presidency may bring uncertainty within the health care sector (NYSEARCA:IYH), but certain pockets of the industry could offer the fundamentals for investors to stay afloat. “We believe ...

SpringWorks Therapeutics shows strong growth with approved drugs and potential for more, making it a promising buy. Read my ...

RBC Capital raised the firm’s price target on Exelixis (EXEL) to $38 from $34 and keeps an Outperform rating on the shares.